


# PRODUCT INFORMATION



## $\alpha$ -hydroxy Alprazolam

Item No. 15287

**CAS Registry No.:** 37115-43-8  
**Formal Name:** 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-1-methanol  
**Synonym:** U-40125  
**MF:** C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>O  
**FW:** 324.8  
**Purity:**  $\geq$ 98%  
**Supplied as:** A neat solid  
**Storage:** -20°C  
**Stability:**  $\geq$ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Description

$\alpha$ -hydroxy Alprazolam (Item No. 15287) is an analytical reference material categorized as a benzodiazepine. It is a major active metabolite of alprazolam (CRM) (Item No. ISO60185) that has a higher urinary recovery than 4-hydroxy alprazolam (Item No. 15878), another major metabolite.<sup>1-3</sup>  $\alpha$ -hydroxy Alprazolam has a lower binding affinity than alprazolam for the GABA<sub>A</sub> receptor.<sup>1</sup> It is also a metabolite of adinazolam (Item No. 18205).<sup>4</sup> This product is intended for research and forensic applications.

This product is qualified as a Reference Material that has been manufactured and tested to ISO/IEC 17025 and ISO 17034 international standards for reference materials.

### References

1. Greenblatt, D.J. and Wright, C.E. Clinical pharmacokinetics of alprazolam. Therapeutic implications. *Clin. Pharmacokinet.* **24(6)**, 453-471 (1993).
2. Shin, M., Ki, D., Kang, S., et al. Screening of multiple drugs of abuse and metabolites in urine using LC/MS/MS with polarity switching electrospray ionization. *Arch. Pharm. Res.* **37(6)**, 760-772 (2014).
3. Allqvist, A., Wennerholm, A., Svensson, J.-O., et al. Simultaneous quantification of alprazolam, 4- and  $\alpha$ -hydroxyalprazolam in plasma samples using liquid chromatography mass spectrometry. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **814(1)**, 127-131 (2005).
4. Fraser, A.D., Isner, A.F., and Bryan, W. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC. *J. Anal. Toxicol.* **17(7)**, 427-431 (1993).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/27/2019

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM